Investment Analysts’ Weekly Ratings Updates for Vaxcyte (PCVX)

Vaxcyte (NASDAQ: PCVX) has recently received a number of price target changes and ratings updates:

• 10/12/2026 – Vaxcyte had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $120.00 price target on the stock.
• 10/5/2026 – Vaxcyte had its price target raised by Guggenheim from $116.00 to $125.00. They now have a “buy” rating on the stock.
• 10/5/2026 – Vaxcyte had its “buy” rating reaffirmed by BTIG Research. They now have a $89.00 price target on the stock.
• 10/5/2026 – Vaxcyte had its price target raised by Needham & Company LLC from $110.00 to $122.00. They now have a “buy” rating on the stock.
• 10/2/2026 – Vaxcyte had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/28/2026 – Vaxcyte had its price target lowered by Bank of America from $133.00 to $130.00. They now have a “buy” rating on the stock.
• 9/25/2026 – Vaxcyte had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $110.00 price target on the stock.

Insider Buying and Selling at Vaxcyte

In other news, insider Harpreet S. Dhaliwal sold 17,000 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total transaction of $935,000.00. Following the completion of the transaction, the insider owned 76,756 shares of the company’s stock, valued at approximately $4,221,580. The trade was a 18.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Elvia Cowan sold 19,000 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $86.74, for a total transaction of $1,648,060.00. Following the transaction, the chief accounting officer owned 27,860 shares of the company’s stock, valued at $2,416,576.40. This trade represents a 40.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 92,890 shares of company stock valued at $6,320,569 in the last quarter. Company insiders own 3.30% of the company’s stock.

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.